Melbourne, Feb 19, 2009 (ABN Newswire) - Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) Net loss after tax was A$1.9 million, with operating cash outflows of A$2.5 million for the half year, 12% less than the same period in the prior year. Cash at 31 December was A$6.1 million. Total revenue and other income was A$5.1 million for the half year with revenue from continuing operations A$1.0 million for the six months, up 6% compared with the same period in the prior year.
Receipts from customers included royalty and license income from partners including SSL International and Dade Behring (part of the Siemens Healthcare group), and grant and contract payments from the U.S. National Institutes of Health for VivaGel(R) development costs. The receipts from SSL International represent the first payment under the strategically important partnership with SSL International for the VivaGel(R) coated condom, which Starpharma has estimated will yield total receipts in excess of A$100m.
Apart from the VivaGel(R) coated condom and stand-alone products, the Company is continuing to focus on near-term commercial partnerships in areas such as drug delivery, cosmetics / personal care products and diagnostics.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
Contact
Dr Jackie Fairley Chief Executive Officer TEL: +61-3-8532-2704
Ben Rogers Company Secretary TEL: +61-3-8532-2702 ben.rogers@starpharma.com
Starpharma Holdings Limited
